Cytek Biosciences, Inc.

Our Board has adopted a non-employee director compensation policy and our Compensation Committee reviews director compensation every two (2) years or more frequently if needed. In evaluating director compensation, the Compensation Committee considers the information, analysis and recommendations provided by Meridian, including data regarding compensation paid to non-employee directors by peer group companies, and seeks to align our director compensation program to market compensation levels and our overall compensation philosophy.

In early 2023, per request of the Compensation Committee, Meridian gathered and analyzed compensation data of the peer group companies used for 2023 executive compensation benchmarking for purposes of reviewing non-employee director compensation (the “Meridian director compensation survey”). The Meridian director compensation survey concluded that the level of compensation of our non-employee directors was between the 25 th and 50 th percentile of the peer group companies. The Meridian director compensation survey recommended an increase in non-employee director compensation to align with the median of the peer group companies. In May 2023, the Compensation Committee recommended and the Board approved an amendment to the non-employee director compensation policy, effective July 1, 2023, to provide for an increase in annual cash retainer paid to non-employee directors from $40,000 to $50,000 and an increase in the value of annual equity awards granted to non-employee directors from $160,000 to $180,000, with 50% of the value of the award composed of stock options and 50% of the value of the award composed of RSUs.